Jason Gardner Ph.D.
Net Worth
Last updated:
What is Jason Gardner Ph.D. net worth?
The estimated net worth of Dr. Jason Gardner Ph.D. is at least $5,649,328 as of 16 Sep 2021. He has earned $96,508 from insider trading and has received compensation worth at least $5,552,820 in Magenta Therapeutics, Inc..
What is the salary of Jason Gardner Ph.D.?
Dr. Jason Gardner Ph.D. salary is $793,260 per year as Co-Founder, Chief Executive Officer, Pres & Director in Magenta Therapeutics, Inc..
How old is Jason Gardner Ph.D.?
Dr. Jason Gardner Ph.D. is 54 years old, born in 1971.
What stocks does Jason Gardner Ph.D. currently own?
As insider, Dr. Jason Gardner Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Magenta Therapeutics, Inc. (MGTA) | Co-Founder, Chief Executive Officer, Pres & Director | 286,872 | $0 | $0 |
What does Magenta Therapeutics, Inc. do?
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Jason Gardner Ph.D. insider trading
Magenta Therapeutics, Inc.
Dr. Jason Gardner Ph.D. has made 8 insider trades between 2018-2021, according to the Form 4 filled with the SEC. Most recently he sold 14,340 units of MGTA stock worth $96,508 on 16 Sep 2021.
The largest trade he's ever made was exercising 76,711 units of MGTA stock on 20 Dec 2019. As of 16 Sep 2021 he still owns at least 286,872 units of MGTA stock.
Magenta Therapeutics key executives
Magenta Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Jason Gardner Ph.D. (54) Co-Founder, Chief Executive Officer, Pres & Director
- Mr. Stephen F. Mahoney J.D., MBA (54) Chief Financial & Operating Officer and Treasurer